Publications & Posters

Plasma Neurofilament Light Chain As A Translational Biomarker Of Aging And Neurodegeneration In Dogs


Panek WK, Gruen ME, Murdoch DM, Marek RD, Stachel AF, Mowat FM, Saker KE and Olby NJ

Mol Neurobiol. 2020 May 30

DOI:  10.1007/s12035-020-01951-0


and humans represent two populations that have experienced a significant increase in average life expectancy over the last century. A higher prevalence of age-related neurodegenerative diseases has been observed across both species, and human diseases, such as Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS), have canine analogs, canine cognitive dysfunction (CCD), and degenerative myelopathy (DM) respectively. In humans, protein biomarkers have proved useful in the prediction and diagnosis of neurodegeneration. Molecular signatures of many proteins are highly conserved across species. In this study, we explored the potential of the neuronal cytoskeletal protein neurofilament light chain (NfL) as a biomarker of neuro-aging in dogs using an ultrasensitive single-molecule array assay to measure plasma concentrations. Healthy dogs of different ages and dogs affected with CCD and DM were evaluated. The mean plasma NfL concentrations in the different age groups of the healthy population were as follows: 4.55 ± 1.70pg/mL in puppy/junior group (0.43-2years), 13.51 ± 6.8pg/mL in adult/mature group (2.1-9years), and 47.1 ± 12.68pg/mL in geriatric/senior group (9.3-14.5years). Concentrations in dogs with DM (7.5-12.6years) and CCD (11.0-15.6years) were 84.17 ± 53.57pg/mL and 100.73 ± 83.72pg/mL, respectively. Plasma NfL increases in an age-dependent manner and is significantly elevated in dogs diagnosed with neurodegenerative disease. This work identified plasma NfL as a key clinical index of neuro-aging and neurodegeneration in pet dogs. Our findings mirror recent reports from human neurodegenerative diseases.